Meeting
2015 ASCO Annual Meeting
A phase 2 study (2-stage, 2-cohort) of the oral PARP inhibitor talazoparib (BMN 673) in patients with germline BRCA mutation and locally advanced and/or metastatic breast cancer (ABRAZO).
Authors
Nicholas C. Turner
Royal Marsden, London & Surrey, United Kingdom
Nicholas C. Turner , Judith Balmaña , Peter A. Fasching , Sara A. Hurvitz , Melinda L. Telli , Fran Visco , Andrew M. Wardley , Charlie Zhang , Nathalie Andrienne Lokker , Debra L. Lounsbury , Mark E. Robson
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Clinical Trial Registration Number
NCT02034916
Citation
J Clin Oncol 33, 2015 (suppl; abstr TPS1108)
DOI
10.1200/jco.2015.33.15_suppl.tps1108
Abstract #
TPS1108
Poster Bd #
218a
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A phase 3, open-label, randomized, parallel, 2-arm international study of the oral PARP inhibitor talazoparib (BMN 673) in BRCA mutation subjects with locally advanced and/or metastatic breast cancer (EMBRACA).
First Author: Jennifer Keating Litton
Poster
2022 ASCO Annual Meeting
DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib.
First Author: Severine Guiu Lahaye
Poster
2021 ASCO Annual Meeting
Safety and efficacy of HX008: A humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma—A single-arm, multicenter, phase II study.
First Author: BIN LIAN
Poster
2021 ASCO Annual Meeting
A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation.
First Author: Tao Sun